메뉴 건너뛰기




Volumn 117, Issue 24, 2011, Pages 5439-5449

Advances and controversies in the diagnosis, pathogenesis, and treatment of systemic mastocytosis

Author keywords

diagnosis; KIT; midostaurin; prognosis; systemic mastocytosis

Indexed keywords

6 (2,6 DICHLOROPHENYL) 2 (4 FLUORO 3 METHYLANILINO) 8 METHYL 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; [4 [2 CYCLOPENTYL 9 (3 HYDROXYPHENETHYL)PURIN 6 YLAMINO]PHENYL]DIMETHYLPHOSPHINE OXIDE; ABELSON KINASE; ALBUMIN; ALPHA INTERFERON; CD2 ANTIGEN; CLADRIBINE; DACLIZUMAB; DASATINIB; DENILEUKIN DIFTITOX; EVEROLIMUS; IMATINIB; INTERLEUKIN 2 RECEPTOR ALPHA; MASITINIB; MIDOSTAURIN; NILOTINIB; OBATOCLAX; OMALIZUMAB; OSI 930; PLACEBO; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; SHORT HAIRPIN RNA; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR; TANDUTINIB; THALIDOMIDE; TRIPTOLIDE; TRYPTASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

EID: 80455151189     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26256     Document Type: Review
Times cited : (26)

References (93)
  • 1
    • 19944434116 scopus 로고    scopus 로고
    • Mastocytosis: Pathology, genetics, and current options for therapy
    • Valent P, Akin C, Sperr WR, et al. Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma. 2005; 46: 35-48.
    • (2005) Leuk Lymphoma. , vol.46 , pp. 35-48
    • Valent, P.1    Akin, C.2    Sperr, W.R.3
  • 2
    • 21344439293 scopus 로고    scopus 로고
    • Systemic mastocytosis: Bone marrow pathology, classification, and current therapies
    • DOI 10.1159/000085561
    • Pardanani A,. Systemic mastocytosis: bone marrow pathology, classification, and current therapies. Acta Haematol. 2005; 114: 41-51. (Pubitemid 40911571)
    • (2005) Acta Haematologica , vol.114 , Issue.1 , pp. 41-51
    • Pardanani, A.1
  • 4
    • 67651120132 scopus 로고    scopus 로고
    • Systemic mastocytosis in 342 consecutive adults: Survival studies and prognostic factors
    • Lim KH, Tefferi A, Lasho TL, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 2009; 113: 5727-5736.
    • (2009) Blood. , vol.113 , pp. 5727-5736
    • Lim, K.H.1    Tefferi, A.2    Lasho, T.L.3
  • 5
    • 74949103091 scopus 로고    scopus 로고
    • WHO subvariants of indolent mastocytosis: Clinical details and prognostic evaluation in 159 consecutive adults
    • Pardanani A, Lim KH, Lasho TL, et al. WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults. Blood. 2010; 115: 150-151.
    • (2010) Blood. , vol.115 , pp. 150-151
    • Pardanani, A.1    Lim, K.H.2    Lasho, T.L.3
  • 6
    • 79952346791 scopus 로고    scopus 로고
    • Isolated bone marrow mastocytosis: An underestimated subvariant of indolent systemic mastocytosis
    • Zanotti R, Bonadonna P, Bonifacio M, et al. Isolated bone marrow mastocytosis: an underestimated subvariant of indolent systemic mastocytosis. Haematologica. 2011; 96: 482-484.
    • (2011) Haematologica. , vol.96 , pp. 482-484
    • Zanotti, R.1    Bonadonna, P.2    Bonifacio, M.3
  • 7
    • 77952745200 scopus 로고    scopus 로고
    • Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms
    • Alvarez-Twose I, Gonzalez de Olano D, Sanchez-Munoz L, et al. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. J Allergy Clin Immunol. 2010; 125: 1269-1278.
    • (2010) J Allergy Clin Immunol. , vol.125 , pp. 1269-1278
    • Alvarez-Twose, I.1    Gonzalez De Olano, D.2    Sanchez-Munoz, L.3
  • 8
    • 77949268924 scopus 로고    scopus 로고
    • Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes
    • Teodosio C, Garcia-Montero AC, Jara-Acevedo M, et al. Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes. J Allergy Clin Immunol. 2010; 125: 719-726.
    • (2010) J Allergy Clin Immunol. , vol.125 , pp. 719-726
    • Teodosio, C.1    Garcia-Montero, A.C.2    Jara-Acevedo, M.3
  • 9
    • 69349102308 scopus 로고    scopus 로고
    • Prognosis in adult indolent systemic mastocytosis: A long-term study of the Spanish Network on Mastocytosis in a series of 145 patients
    • Escribano L, Alvarez-Twose I, Sanchez-Munoz L, et al. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol. 2009; 124: 514-521.
    • (2009) J Allergy Clin Immunol. , vol.124 , pp. 514-521
    • Escribano, L.1    Alvarez-Twose, I.2    Sanchez-Munoz, L.3
  • 11
    • 33748615147 scopus 로고    scopus 로고
    • Molecular diagnosis of mast cell disorders: A paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology
    • DOI 10.2353/jmoldx.2006.060022
    • Akin C,. Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn. 2006; 8: 412-419. (Pubitemid 44377921)
    • (2006) Journal of Molecular Diagnostics , vol.8 , Issue.4 , pp. 412-419
    • Akin, C.1
  • 12
    • 70449706224 scopus 로고    scopus 로고
    • Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies
    • Pardanani A, Lim KH, Lasho TL, et al. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood. 2009; 114: 3769-3772.
    • (2009) Blood. , vol.114 , pp. 3769-3772
    • Pardanani, A.1    Lim, K.H.2    Lasho, T.L.3
  • 13
    • 0034766591 scopus 로고    scopus 로고
    • Bone marrow mast cell morphologic features and hematopoietic dyspoiesis in systemic mast cell disease
    • DOI 10.1309/Q2WJ-46CL-YRFT-M5JF
    • Stevens EC, Rosenthal NS,. Bone marrow mast cell morphologic features and hematopoietic dyspoiesis in systemic mast cell disease. Am J Clin Pathol. 2001; 116: 177-182. (Pubitemid 33044321)
    • (2001) American Journal of Clinical Pathology , vol.116 , Issue.2 , pp. 177-182
    • Stevens, E.C.1    Rosenthal, N.S.2
  • 14
    • 2942596256 scopus 로고    scopus 로고
    • Bone marrow mast cell immunophenotyping in adults with mast cell disease: A prospective study of 33 patients
    • DOI 10.1016/j.leukres.2003.10.035, PII S0145212603004168
    • Pardanani A, Kimlinger T, Reeder T, Li CY, Tefferi A,. Bone marrow mast cell immunophenotyping in adults with mast cell disease: a prospective study of 33 patients. Leuk Res. 2004; 28: 777-783. (Pubitemid 38760039)
    • (2004) Leukemia Research , vol.28 , Issue.8 , pp. 777-783
    • Pardanani, A.1    Kimlinger, T.2    Reeder, T.3    Li, C.-Y.4    Tefferi, A.5
  • 15
    • 33846099538 scopus 로고    scopus 로고
    • FIP1L1/PDGFRA is a molecular marker of chronic eosinophilic leukaemia but not for systemic mastocytosis [1]
    • DOI 10.1111/j.1365-2362.2007.01757.x
    • Valent P, Akin C, Metcalfe DD,. FIP1L1/PDGFRA is a molecular marker of chronic eosinophilic leukaemia but not for systemic mastocytosis. Eur J Clin Invest. 2007; 37: 153-154. (Pubitemid 46066495)
    • (2007) European Journal of Clinical Investigation , vol.37 , Issue.2 , pp. 153-154
    • Valent, P.1    Akin, C.2    Metcalfe, D.D.3
  • 16
    • 58149161786 scopus 로고    scopus 로고
    • Utility of the World Heath Organization classification criteria for the diagnosis of systemic mastocytosis in bone marrow
    • Johnson MR, Verstovsek S, Jorgensen JL, et al. Utility of the World Heath Organization classification criteria for the diagnosis of systemic mastocytosis in bone marrow. Mod Pathol. 2009; 22: 50-57.
    • (2009) Mod Pathol. , vol.22 , pp. 50-57
    • Johnson, M.R.1    Verstovsek, S.2    Jorgensen, J.L.3
  • 17
    • 67049095733 scopus 로고    scopus 로고
    • Mastocytosis. A disease of the hematopoietic stem cell
    • Homann J, Kolck U, Molderings GJ,. Mastocytosis. A disease of the hematopoietic stem cell. Dtsch Arztebl Int. 2009; 106: 173-174.
    • (2009) Dtsch Arztebl Int. , vol.106 , pp. 173-174
    • Homann, J.1    Kolck, U.2    Molderings, G.J.3
  • 18
    • 34548690793 scopus 로고    scopus 로고
    • Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with "idiopathic" anaphylaxis
    • DOI 10.1182/blood-2006-06-028100
    • Akin C, Scott LM, Kocabas CN, et al. Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with "idiopathic" anaphylaxis. Blood. 2007; 110: 2331-2333. (Pubitemid 47523152)
    • (2007) Blood , vol.110 , Issue.7 , pp. 2331-2333
    • Akin, C.1    Scott, L.M.2    Kocabas, C.N.3    Kushnir-Sukhov, N.4    Brittain, E.5    Noel, P.6    Metcalfe, D.D.7
  • 19
    • 77949865698 scopus 로고    scopus 로고
    • Variable presence of KITD816V in clonal haematological non-mast lineage diseases associated with systemic mastocytosis (SM-AHNMD)
    • Sotlar K, Colak S, Bache A, et al. Variable presence of KITD816V in clonal haematological non-mast lineage diseases associated with systemic mastocytosis (SM-AHNMD). J Pathol. 2010; 220: 586-595.
    • (2010) J Pathol. , vol.220 , pp. 586-595
    • Sotlar, K.1    Colak, S.2    Bache, A.3
  • 20
    • 78649498791 scopus 로고    scopus 로고
    • Phenotypic heterogeneity, novel diagnostic markers, and target expression profiles in normal and neoplastic human mast cells
    • Valent P, Cerny-Reiterer S, Herrmann H, et al. Phenotypic heterogeneity, novel diagnostic markers, and target expression profiles in normal and neoplastic human mast cells. Best Pract Res Clin Haematol. 2010; 23: 369-378.
    • (2010) Best Pract Res Clin Haematol. , vol.23 , pp. 369-378
    • Valent, P.1    Cerny-Reiterer, S.2    Herrmann, H.3
  • 21
    • 38549127753 scopus 로고    scopus 로고
    • How we diagnose and treat WHO-defined systemic mastocytosis in adults
    • DOI 10.3324/haematol.12324
    • Tefferi A, Verstovsek S, Pardanani A,. How we diagnose and treat WHO-defined systemic mastocytosis in adults. Haematologica. 2008; 93: 6-9. (Pubitemid 351156144)
    • (2008) Haematologica , vol.93 , Issue.1 , pp. 6-9
    • Tefferi, A.1    Verstovsek, S.2    Pardanani, A.3
  • 22
    • 0018096538 scopus 로고
    • Decrease of mast cells in W/W(V) mice and their increase by bone marrow transplantation
    • Kitamura Y, Go S, Hatanaka K,. Decrease of mast cells in W/Wv mice and their increase by bone marrow transplantation. Blood. 1978; 52: 447-452. (Pubitemid 8395558)
    • (1978) Blood , vol.52 , Issue.2 , pp. 447-452
    • Kitamura, Y.1    Go, S.2    Hatanaka, K.3
  • 23
    • 0018344526 scopus 로고
    • Decreased production of mast cells in S1/S1(d) anemic mice
    • Kitamura Y, Go S,. Decreased production of mast cells in S1/S1d anemic mice. Blood. 1979; 53: 492-497. (Pubitemid 9140406)
    • (1979) Blood , vol.53 , Issue.3 , pp. 492-497
    • Kitamura, Y.1    Go, S.2
  • 24
    • 0028856070 scopus 로고
    • Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder
    • Nagata H, Worobec AS, Oh CK, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A. 1995; 92: 10560-10564.
    • (1995) Proc Natl Acad Sci U S A. , vol.92 , pp. 10560-10564
    • Nagata, H.1    Worobec, A.S.2    Oh, C.K.3
  • 26
    • 44849118922 scopus 로고    scopus 로고
    • Phenotypic and genotypic characteristics of mastocytosis according to the age of onset [serial online]
    • Lanternier F, Cohen-Akenine A, Palmerini F, et al. Phenotypic and genotypic characteristics of mastocytosis according to the age of onset [serial online]. PLoS One. 2008; 3: e1906.
    • (2008) PLoS One. , vol.3
    • Lanternier, F.1    Cohen-Akenine, A.2    Palmerini, F.3
  • 29
    • 3442893823 scopus 로고    scopus 로고
    • The biology of Kit in disease and the application of pharmacogenetics
    • DOI 10.1016/j.jaci.2004.04.046, PII S0091674904014174
    • Akin C, Metcalfe DD,. The biology of Kit in disease and the application of pharmacogenetics. J Allergy Clin Immunol. 2004; 114: 13-19; quiz 20. (Pubitemid 39005112)
    • (2004) Journal of Allergy and Clinical Immunology , vol.114 , Issue.1 , pp. 13-19
    • Akin, C.1    Metcalfe, D.D.2
  • 30
    • 54349125809 scopus 로고    scopus 로고
    • Delineation of the KIT-independent oncogenic pathway in neoplastic mast cells that involves Lyn and Btk and can be disrupted with the KIT/Lyn/Btk-targeting drug dasatinib
    • Gleixner K, Mayerhofer M, Rix U, et al. Delineation of the KIT-independent oncogenic pathway in neoplastic mast cells that involves Lyn and Btk and can be disrupted with the KIT/Lyn/Btk-targeting drug dasatinib. Blood. 2007; 110: 460a-461a.
    • (2007) Blood. , vol.110
    • Gleixner, K.1    Mayerhofer, M.2    Rix, U.3
  • 32
    • 67349145955 scopus 로고    scopus 로고
    • Frequent TET2 mutations in systemic mastocytosis: Clinical, KITD816V and FIP1L1-PDGFRA correlates
    • Tefferi A, Levine RL, Lim KH, et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia. 2009; 23: 900-904.
    • (2009) Leukemia. , vol.23 , pp. 900-904
    • Tefferi, A.1    Levine, R.L.2    Lim, K.H.3
  • 33
    • 84983656671 scopus 로고    scopus 로고
    • New TET2, ASXL1, and CBL mutations have poor prognostic impact in systemic mastocytosis and related disorders [abstract]
    • Abstract 3076.
    • Traina F, Jankowska A, Makishima H, et al. New TET2, ASXL1, and CBL mutations have poor prognostic impact in systemic mastocytosis and related disorders [abstract]. Blood (ASH Annual Meeting Abstracts). 2010; 116. Abstract 3076.
    • (2010) Blood (ASH Annual Meeting Abstracts). , vol.116
    • Traina, F.1    Jankowska, A.2    Makishima, H.3
  • 34
    • 79952336888 scopus 로고    scopus 로고
    • Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis
    • Wilson T, Maric I, Simakova O, et al. Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis. Haematologica. 2011; 96: 459-463.
    • (2011) Haematologica. , vol.96 , pp. 459-463
    • Wilson, T.1    Maric, I.2    Simakova, O.3
  • 35
    • 78651060064 scopus 로고    scopus 로고
    • Gene expression profile, pathways, and transcriptional system regulation in indolent systemic mastocytosis
    • Niedoszytko M, Oude Elberink JN, Bruinenberg M, et al. Gene expression profile, pathways, and transcriptional system regulation in indolent systemic mastocytosis. Allergy. 2011; 66: 229-237.
    • (2011) Allergy. , vol.66 , pp. 229-237
    • Niedoszytko, M.1    Oude Elberink, J.N.2    Bruinenberg, M.3
  • 38
    • 34250826484 scopus 로고    scopus 로고
    • Successful treatment of cutaneous mastocytosis and Méniere disease with anti-IgE therapy
    • DOI 10.1016/j.jaci.2007.05.011, PII S0091674907009566
    • Siebenhaar F, Kuhn W, Zuberbier T, Maurer M,. Successful treatment of cutaneous mastocytosis and Meniere disease with anti-IgE therapy. J Allergy Clin Immunol. 2007; 120: 213-215. (Pubitemid 46990509)
    • (2007) Journal of Allergy and Clinical Immunology , vol.120 , Issue.1 , pp. 213-215
    • Siebenhaar, F.1    Kuhn, W.2    Zuberbier, T.3    Maurer, M.4
  • 39
    • 0031943841 scopus 로고    scopus 로고
    • Response of severe systemic mastocytosis to interferon alpha
    • DOI 10.1046/j.1365-2133.1998.02131.x
    • Butterfield JH,. Response of severe systemic mastocytosis to interferon alpha. Br J Dermatol. 1998; 138: 489-495. (Pubitemid 28145521)
    • (1998) British Journal of Dermatology , vol.138 , Issue.3 , pp. 489-495
    • Butterfield, J.H.1
  • 41
    • 0346154747 scopus 로고    scopus 로고
    • Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: Report of five cases and review of the literature
    • DOI 10.1016/S0145-2126(03)00259-5
    • Hauswirth AW, Simonitsch-Klupp I, Uffmann M, et al. Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of 5 cases and review of the literature. Leuk Res. 2004; 28: 249-257. (Pubitemid 37550059)
    • (2004) Leukemia Research , vol.28 , Issue.3 , pp. 249-257
    • Hauswirth, A.W.1    Simonitsch-Klupp, I.2    Uffmann, M.3    Koller, E.4    Sperr, W.R.5    Lechner, K.6    Valent, P.7
  • 42
    • 73349111582 scopus 로고    scopus 로고
    • Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine
    • Lim KH, Pardanani A, Butterfield JH, Li CY, Tefferi A,. Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol. 2009; 84: 790-794.
    • (2009) Am J Hematol. , vol.84 , pp. 790-794
    • Lim, K.H.1    Pardanani, A.2    Butterfield, J.H.3    Li, C.Y.4    Tefferi, A.5
  • 43
    • 84858268181 scopus 로고    scopus 로고
    • Long term efficacy and safety of cladribine in adult systemic mastocytosis: A French multicenter study of 44 patients [abstract]
    • Abstract 1982.
    • Hermine O, Hirsh I, Damaj G, et al. Long term efficacy and safety of cladribine in adult systemic mastocytosis: a French multicenter study of 44 patients [abstract]. Blood (ASH Annual Meeting Abstracts). 2010; 116. Abstract 1982.
    • (2010) Blood (ASH Annual Meeting Abstracts). , vol.116
    • Hermine, O.1    Hirsh, I.2    Damaj, G.3
  • 44
    • 20144379077 scopus 로고    scopus 로고
    • Efficacy and safety of cladribine in adult systemic mastocytosis: A French multicenter study of 33 patients [abstract]
    • Abstract 661.
    • Lortholary O, Vargaftig J, Feger F, et al. Efficacy and safety of cladribine in adult systemic mastocytosis: a French multicenter study of 33 patients [abstract]. Blood (ASH Annual Meeting Abstracts). 2004; 104. Abstract 661.
    • (2004) Blood (ASH Annual Meeting Abstracts). , vol.104
    • Lortholary, O.1    Vargaftig, J.2    Feger, F.3
  • 47
  • 48
    • 0034254249 scopus 로고    scopus 로고
    • Inhibition of c-kit receptor tyrosine kinase activity by STI 571 a selective tyrosine kinase inhibitor
    • Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ,. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000; 96: 925-932. (Pubitemid 30618049)
    • (2000) Blood , vol.96 , Issue.3 , pp. 925-932
    • Heinrich, M.C.1    Griffith, D.J.2    Druker, B.J.3    Wait, C.L.4    Ott, K.A.5    Zigler, A.J.6
  • 50
    • 68649118339 scopus 로고    scopus 로고
    • Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis
    • Vega-Ruiz A, Cortes JE, Sever M, et al. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res. 2009; 33: 1481-1484.
    • (2009) Leuk Res. , vol.33 , pp. 1481-1484
    • Vega-Ruiz, A.1    Cortes, J.E.2    Sever, M.3
  • 52
    • 33947520803 scopus 로고    scopus 로고
    • Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation
    • DOI 10.1038/labinvest.3700524, PII 3700524
    • Nakagomi N, Hirota S,. Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation. Lab Invest. 2007; 87: 365-371. (Pubitemid 46474567)
    • (2007) Laboratory Investigation , vol.87 , Issue.4 , pp. 365-371
    • Nakagomi, N.1    Hirota, S.2
  • 54
    • 52049089936 scopus 로고    scopus 로고
    • Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases
    • Heinrich MC, Joensuu H, Demetri GD, et al. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res. 2008; 14: 2717-2725.
    • (2008) Clin Cancer Res. , vol.14 , pp. 2717-2725
    • Heinrich, M.C.1    Joensuu, H.2    Demetri, G.D.3
  • 56
    • 71849087531 scopus 로고    scopus 로고
    • A phase II study of AMN107, a novel tyrosine kinase inhibitor, administered to patients (pts) with systemic mastocytosis (SM) [abstract]
    • Abstract 6588.
    • Schatz M, Verhoef G, Gattermann N, et al. A phase II study of AMN107, a novel tyrosine kinase inhibitor, administered to patients (pts) with systemic mastocytosis (SM) [abstract]. J Clin Oncol. 2006; 24 (18S). Abstract 6588.
    • (2006) J Clin Oncol. , vol.24 , Issue.18
    • Schatz, M.1    Verhoef, G.2    Gattermann, N.3
  • 58
    • 33645687784 scopus 로고    scopus 로고
    • D816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis
    • DOI 10.1182/blood-2005-10-3969
    • Shah NP, Lee FY, Luo R, Jiang Y, Donker M, Akin C,. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood. 2006; 108: 286-291. (Pubitemid 43990640)
    • (2006) Blood , vol.108 , Issue.1 , pp. 286-291
    • Shah, N.P.1    Lee, F.Y.2    Luo, R.3    Jiang, Y.4    Donker, M.5    Akin, C.6
  • 60
    • 52449085884 scopus 로고    scopus 로고
    • Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis
    • Verstovsek S, Tefferi A, Cortes J, et al. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res. 2008; 14: 3906-3915.
    • (2008) Clin Cancer Res. , vol.14 , pp. 3906-3915
    • Verstovsek, S.1    Tefferi, A.2    Cortes, J.3
  • 61
    • 54349097778 scopus 로고    scopus 로고
    • Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis
    • Aichberger KJ, Sperr WR, Gleixner KV, Kretschmer A, Valent P,. Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis. Eur J Clin Invest. 2008; 38: 869-873.
    • (2008) Eur J Clin Invest. , vol.38 , pp. 869-873
    • Aichberger, K.J.1    Sperr, W.R.2    Gleixner, K.V.3    Kretschmer, A.4    Valent, P.5
  • 65
    • 79960404044 scopus 로고    scopus 로고
    • KIT inhibitor midostaurin exhibits a high rate of clinically meaningful and durable responses in advanced systemic mastocytosis: Report of a fully accrued phase II trial [abstract]
    • Abstract 316.
    • Gotlib J, DeAngelo DJ, George TI, et al. KIT inhibitor midostaurin exhibits a high rate of clinically meaningful and durable responses in advanced systemic mastocytosis: report of a fully accrued phase II trial [abstract]. Blood (ASH Annual Meeting Abstracts). 2010; 116. Abstract 316.
    • (2010) Blood (ASH Annual Meeting Abstracts). , pp. 116
    • Gotlib, J.1    Deangelo, D.J.2    George, T.I.3
  • 66
    • 77951066096 scopus 로고    scopus 로고
    • A critical reappraisal of treatment response criteria in systemic mastocytosis and a proposal for revisions
    • Pardanani A, Tefferi A,. A critical reappraisal of treatment response criteria in systemic mastocytosis and a proposal for revisions. Eur J Haematol. 2010; 84: 371-378.
    • (2010) Eur J Haematol. , vol.84 , pp. 371-378
    • Pardanani, A.1    Tefferi, A.2
  • 67
    • 70349658639 scopus 로고    scopus 로고
    • Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT [serial online]
    • Dubreuil P, Letard S, Ciufolini M, et al. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT [serial online]. PLoS One. 2009; 4: e7258.
    • (2009) PLoS One. , vol.4
    • Dubreuil, P.1    Letard, S.2    Ciufolini, M.3
  • 68
    • 57149112342 scopus 로고    scopus 로고
    • Masitinib is safe and effective for the treatment of canine mast cell tumors
    • Hahn KA, Ogilvie G, Rusk T, et al. Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med. 2008; 22: 1301-1309.
    • (2008) J Vet Intern Med. , vol.22 , pp. 1301-1309
    • Hahn, K.A.1    Ogilvie, G.2    Rusk, T.3
  • 69
    • 78649504351 scopus 로고    scopus 로고
    • Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: A phase 2a study
    • Paul C, Sans B, Suarez F, et al. Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study. Am J Hematol. 2010; 85: 921-925.
    • (2010) Am J Hematol. , vol.85 , pp. 921-925
    • Paul, C.1    Sans, B.2    Suarez, F.3
  • 72
    • 0034095603 scopus 로고    scopus 로고
    • The pyrido[2,3-d]pyrimidine derivative PD180970 inhibits p210(Bcr-Abl) tyrosine kinase and induces apoptosis of K562 leukemic cells
    • Dorsey J, Jove R, Kraker AJ, et al. The pyrido[2,3-d]pyrimidine derivative PD180970 inhibits p210 Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells. Cancer Res. 2000; 60: 3127-3131. (Pubitemid 30407904)
    • (2000) Cancer Research , vol.60 , Issue.12 , pp. 3127-3131
    • Dorsey, J.F.1    Jove, R.2    Kraker, A.J.3    Wu, J.4
  • 75
    • 0037100281 scopus 로고    scopus 로고
    • Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors
    • DOI 10.1182/blood-2001-12-0350
    • Liao A, Chien MB, Shenoy N, et al. Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors. Blood. 2002; 100: 585-593. (Pubitemid 34761123)
    • (2002) Blood , vol.100 , Issue.2 , pp. 585-593
    • Liao, A.T.1    Chien, M.B.2    Shenoy, N.3    Mendel, D.B.4    McMahon, G.5    Cherrington, J.M.6    London, C.A.7
  • 84
    • 76349119028 scopus 로고    scopus 로고
    • Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis
    • Parikh SA, Kantarjian HM, Richie MA, Cortes JE, Verstovsek S,. Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis. Leuk Lymphoma. 2010; 51: 269-274.
    • (2010) Leuk Lymphoma. , vol.51 , pp. 269-274
    • Parikh, S.A.1    Kantarjian, H.M.2    Richie, M.A.3    Cortes, J.E.4    Verstovsek, S.5
  • 86
    • 77954659778 scopus 로고    scopus 로고
    • Inhibition of JAK-STAT signaling by TG101348: A novel mechanism for inhibition of KITD816V-dependent growth in mast cell leukemia cells
    • Lasho T, Tefferi A, Pardanani A,. Inhibition of JAK-STAT signaling by TG101348: a novel mechanism for inhibition of KITD816V-dependent growth in mast cell leukemia cells. Leukemia. 2010; 24: 1378-1380.
    • (2010) Leukemia. , vol.24 , pp. 1378-1380
    • Lasho, T.1    Tefferi, A.2    Pardanani, A.3
  • 87
    • 73949158887 scopus 로고    scopus 로고
    • Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: Role of KIT D816V and effects of various targeted drugs
    • Aichberger KJ, Gleixner KV, Mirkina I, et al. Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs. Blood. 2009; 114: 5342-5351.
    • (2009) Blood. , vol.114 , pp. 5342-5351
    • Aichberger, K.J.1    Gleixner, K.V.2    Mirkina, I.3
  • 88
    • 23744515285 scopus 로고    scopus 로고
    • Stem cell factor promotes mast cell survival via inactivation of FOXO3a-mediated transcriptional induction and MEK-regulated phosphorylation of the proapoptotic protein Bim
    • DOI 10.1182/blood-2004-12-4792
    • Moller C, Alfredsson J, Engstrom M, et al. Stem cell factor promotes mast cell survival via inactivation of FOXO3a-mediated transcriptional induction and MEK-regulated phosphorylation of the proapoptotic protein Bim. Blood. 2005; 106: 1330-1336. (Pubitemid 41129597)
    • (2005) Blood , vol.106 , Issue.4 , pp. 1330-1336
    • Moller, C.1    Alfredsson, J.2    Engstrom, M.3    Wootz, H.4    Xiang, Z.5    Lennartsson, J.6    Jonsson, J.-I.7    Nilsson, G.8
  • 89
    • 72249112779 scopus 로고    scopus 로고
    • Selective RNAi-mediated inhibition of mutated c-kit
    • Ruano I, Izquierdo M,. Selective RNAi-mediated inhibition of mutated c-kit. J RNAi Gene Silencing. 2009; 5: 339-344.
    • (2009) J RNAi Gene Silencing. , vol.5 , pp. 339-344
    • Ruano, I.1    Izquierdo, M.2
  • 90
    • 72249084733 scopus 로고    scopus 로고
    • Combination of KIT gene silencing and tocopherol succinate may offer improved therapeutic approaches for human mastocytosis
    • Ruano I, Gargini R, Izquierdo M,. Combination of KIT gene silencing and tocopherol succinate may offer improved therapeutic approaches for human mastocytosis. Br J Haematol. 2010; 148: 59-68.
    • (2010) Br J Haematol. , vol.148 , pp. 59-68
    • Ruano, I.1    Gargini, R.2    Izquierdo, M.3
  • 91
    • 67449095163 scopus 로고    scopus 로고
    • Activity of triptolide against human mast cells harboring the kinase domain mutant KIT
    • Jin Y, Chen Q, Shi X, et al. Activity of triptolide against human mast cells harboring the kinase domain mutant KIT. Cancer Sci. 2009; 100: 1335-1343.
    • (2009) Cancer Sci. , vol.100 , pp. 1335-1343
    • Jin, Y.1    Chen, Q.2    Shi, X.3
  • 92
    • 73949151915 scopus 로고    scopus 로고
    • The antitumor activity of homoharringtonine against human mast cells harboring the KIT D816V mutation
    • Jin Y, Lu Z, Cao K, et al. The antitumor activity of homoharringtonine against human mast cells harboring the KIT D816V mutation. Mol Cancer Ther. 2010; 9: 21-23.
    • (2010) Mol Cancer Ther. , vol.9 , pp. 21-23
    • Jin, Y.1    Lu, Z.2    Cao, K.3
  • 93
    • 52049125709 scopus 로고    scopus 로고
    • The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors
    • Lin TY, Bear M, Du Z, et al. The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors. Exp Hematol. 2008; 36: 1266-1277.
    • (2008) Exp Hematol. , vol.36 , pp. 1266-1277
    • Lin, T.Y.1    Bear, M.2    Du, Z.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.